Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Rx Import Controls Included In Tauzin/Dingell Bioterrorism Bill

Executive Summary

The House Energy & Commerce Committee bioterrorism bill would increase controls on the importation of pharmaceuticals

You may also be interested in...



Rx Import-For-Export Is Among Issues Holding Up Bioterrorism/PDUFA Bill

Rx import controls are among the remaining issues that need to be reconciled in the bioterrorism/Prescription Drug User Fee Act conference legislation to complete a consensus bill by Memorial Day

Rx Import-For-Export Is Among Issues Holding Up Bioterrorism/PDUFA Bill

Rx import controls are among the remaining issues that need to be reconciled in the bioterrorism/Prescription Drug User Fee Act conference legislation to complete a consensus bill by Memorial Day

FDA’s 2002 Regulatory Agenda, In Brief

IRB registration: FDA to propose rule requiring institutional review boards to register with the agency. Registration information would include name of institution operating the IRB, detailed contact information for "the senior officer of the institution and IRB chair or contact, the range of active protocols...involving FDA-regulated products reviewed in previous calendar year, and a description of the types of...products reviewed." The rule is intended to "make it easier for FDA to inspect IRBs and to convey information to IRBs," HHS' Unified Agenda for 2002 explains. FDA is also endorsing a voluntary IRB accreditation system...

Related Content

UsernamePublicRestriction

Register

PS038984

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel